CANNABINOID PHARMACOLOGY/THERAPEUTICS IN CHRONIC DEGENERATIVE DISORDERS AFFECTING THE CENTRAL NERVOUS SYSTEM

Maria S. Aymerich1,2,3, Ester Aso4,5, Miguel A. Abellanas1,2, Rosa M. Tolon6, Jose A. Ramos5,7,8, Isidre Ferrer4,5, Julian Romero6, Javier Fernández-Ruiz5,7,8

1Universidad de Navarra, Facultad de Ciencias, Departamento de Bioquímica y Genética, Pamplona, Spain
2Universidad de Navarra, CIMA, Programa de Neurociencias, Pamplona, Spain
3IdiSNA, Instituto de Investigación Sanitaria de Navarra, Spain
4Departamento de Patología y Terapéutica experimental, Universidad de Barcelona, L’Hospitalet de Llobregat, Spain
5CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Spain
6Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain
7Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain
8IRYCIS, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
Abstract

The endocannabinoid system (ECS) exerts a modulatory effect of important functions such as neurotransmission, glial activation, oxidative stress, or protein homeostasis. Dysregulation of these cellular processes is a common neuropathological hallmark in aging and in neurodegenerative diseases of the central nervous system (CNS). The broad spectrum of actions of cannabinoids allows targeting different aspects of these multifactorial diseases. In this review, we examine the therapeutic potential of the ECS for the treatment of chronic neurodegenerative diseases of the CNS focusing on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. First, we describe the localization of the molecular components of the ECS and how they are altered under neurodegenerative conditions, either contributing to or protecting cells from degeneration. Second, we address recent advances in the modulation of the ECS using experimental models through different strategies including the direct targeting of cannabinoid receptors with agonists or antagonists, increasing the endocannabinoid tone by the inhibition of endocannabinoid hydrolysis, and activation of cannabinoid receptor-independent effects. Preclinical evidence indicates that cannabinoid pharmacology is complex but supports the therapeutic potential of targeting the ECS. Third, we review the clinical evidence and discuss the future perspectives on how to bridge human and animal studies to develop cannabinoid-based therapies for each neurodegenerative disorder. Finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to each disease and the multiple unexplored pathways in cannabinoid pharmacology that could be useful for the treatment of neurodegenerative diseases.
Abbreviations

Aβ: amyloid-beta
AD: Alzheimer’s disease
AEA: anandamide
2-AG: 2-arachidonoylglycerol
ALS: amyotrophic lateral sclerosis
APP: amyloid precursor protein
BBB: blood–brain barrier
BDNF: brain-derived neurotrophic factor
CB₁: cannabinoid receptor type-1
CB₂: cannabinoid receptor type-2
CBD: cannabidiol
CBG: cannabigerol
CNS: central nervous system
DAGL: diacylglycerol lipase
ECS: endocannabinoid system
FAAH: fatty acid amide hydrolase
FTD: frontotemporal lobar dementia
FUS: fused in sarcoma protein
GPe: external segment of the globus pallidus
GPi: internal segment of the globus pallidus
GSK3β: glycogen synthase kinase 3β
HD: Huntington’s disease
L-dopa: L-3,4-dihydroxyphenylalanine
LID: L-dopa-induced dyskinesia
LPS: lipopolysaccharide
MAGL: monoacylglycerol lipase
MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NAPE-PLD: N-arachidonoyl-phosphatidylethanolamine phospholipase D
NMDA: N-methyl D-aspartate
NO: nitric oxide
iNOS: inducible nitric oxide synthase
PET: positron emission tomography
PD: Parkinson’s disease
PPAR\(\gamma\): peroxisome proliferator-activated receptor \(\gamma\)
ROS: reactive oxygen species
SN: substantia nigra
SNpc: substantia nigra pars compacta
SNpr: substantia nigra pars reticulata
SOD: superoxide dismutase
STN: subthalamic nucleus
TDP-43: TAR-DNA-binding protein 43
\(\Delta^9\)-THC: \(\Delta^9\)-tetrahydrocannabinol
1. Common features and challenges in the cannabinoid research in neurodegenerative diseases

Neurodegenerative diseases affecting the central nervous system (CNS), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and others, are characterized by the progressive loss of specific neuronal subpopulations that affect selective regions of the brain and the spinal cord and neurotransmitter systems, thereby leading to different clinical features [1]. Because aging is the major risk factor for these diseases, the prevalence of degenerative disorders of the CNS is expected to increase in the next decades [2]. Currently, there is no cure for any of these disorders. Available treatments provide transient temporary symptomatic relief, but they are poorly active in the underlying disease progression. Seeking molecules with disease-modifying activity is one of the greatest challenges demanded by patients affected by these diseases [3]. Abnormal protein accumulation, impairment of the lysosomal system, excitotoxicity, oxidative stress, and neuroinflammation are classic hallmarks of the aged brain and neurodegenerative conditions [4]. The endocannabinoid system (ECS) has the ability to modulate these common traits in neurodegeneration, thus emerging as a viable target for symptom alleviation or disease progression based on pharmacological modulation of endocannabinoid signaling [5]. Cannabinoids provide a broad-spectrum profile, which is particularly interesting when dealing with complex pathologies of multifactorial origin [6]. The pleiotropic properties of cannabinoids confer the cannabinoids as important molecules for the development of neuroprotective strategies. Endocannabinoid signaling involves cannabinoid receptor-dependent effects (e.g., activation of cannabinoid type-1 (CB₁) receptors to normalize glutamate homeostasis or to activate autophagy, activation of cannabinoid type-2 (CB₂) receptors and peroxisome
proliferator-activated receptor γ (PPARγ), or modulation of G-protein receptor 55 (GPR55) to reduce local inflammatory events) and also cannabinoid receptor-independent effects to reduce oxidative stress, all of which may ultimately promote neuron survival [7]. The key localization of ECS elements in the CNS and their alteration under pathological conditions suggest that this system participates in crucial processes for balancing neurodegeneration/neuroprotection (Fig. 1). This review focuses on how the components of the ECS are altered in chronic degenerative diseases affecting the CNS, such as AD, PD, HD, and ALS (see footnote #1), and indicates that bioactivity of endocannabinoid-based therapies is likely to vary depending on the disease type and the stage at the time of treatment. The review emphasizes on recent advances in preclinical evidence that provides scientific support to propose cannabinoids for the treatment of different neurodegenerative conditions and discusses the future perspectives of cannabinoid-based therapies for the treatment of each neurological disorder.

2. Cannabinoid pharmacology in Alzheimer’s disease

AD is the most common form of dementia among the elderly, and it is defined as a progressive decline of cognition, memory, and other mental functions. The morphological hallmarks of brains affected by AD include amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated microtubule-associated tau protein, which induce neuronal death and impaired interneuronal communication,

FOOTNOTE #1:

Other neurological disorders with degenerative components (e.g., multiple sclerosis and spinal injury) affecting the peripheral nervous system rather than the central nervous system have been reviewed in other articles within this Special Issue; therefore, they are not addressed here.
and these hallmarks progress from the brain stem and inner parts of the temporal lobes to the major part of the whole telencephalon [8]. In fact, most of the experimental models of AD are based on exogenous administration or genetic manipulation for overexpressing Aβ and/or hyperphosphorylated tau in cell cultures or rodent models [9]. Although they have some limitations because they do not fully replicate the AD pathology, those experimental models based on Aβ and/or hyperphosphorylated tau have significantly contributed to AD research.

However, other multiple alterations converge in the pathogenesis of AD, including synaptic degeneration, mitochondrial defects, and increased production of reactive oxygen species (ROS). In addition, inflammatory responses to protein aggregation/deposition, altered neurotransmission, and production of other neuromodulators, together with a vascular dysfunction and impaired degradation pathways, are assumed to play crucial roles in AD progression also [10][11]. Current available therapies against AD produce mild improvement of cognitive and functional capacities [12]. These therapies act on a single target and are administered after clinical manifestations, when there is no turning back for certain pathological events. The progression from early stages of the neurodegenerative process to symptomatic stages may take decades, whereas once the dementia symptoms appear, the disease progression accelerates causing devastating effects [10]. Therefore, two of the major goals of current research in AD are to develop new tools for early diagnosis and to search for treatments that are more effective aimed at curbing or retarding disease progression toward dementia by acting on multiple targets during the prodromal period of the disease.

In this context, targeting the ECS has attracted growing interest during the last decade based on the numerous findings revealing that the stimulation of ECS contributes to modulate in parallel several of the pathological processes occurring during the early
stages of AD, thereby conferring cannabinoid compounds a potential utility against this neurodegenerative disease, as summarized below.

2.1. The endocannabinoid system in Alzheimer’s disease

Neuropathological changes in AD trigger a potent neuroinflammatory reaction in which glial cells (astrocytes and microglia) become a source of increased cytokine production [13]. In this context, the ECS becomes profoundly altered, with modifications ranging from changes in anandamide (AEA) and 2-arachidonoylglycerol (2-AG) levels to the expression pattern of their regulatory enzymes and of cannabinoid receptors [14].

A seminal study by Westlake et al [15] showed a significant decrease in CB$_1$ receptors in tissue sections from AD donors, as measured by autoradiography, probably because of the neuronal loss associated with this disease. Further studies, however, have not confirmed these observations. For instance, no changes in CB$_1$ receptor levels were found by immunoblotting and receptor binding in human brain samples [16]. In addition, an in vivo study conducted in 11 patients with AD and 7 healthy volunteers by using the specific radiotracer $[^{18}F]$MK-9470 for positron emission tomography (PET) of CB$_1$ receptors found no significant differences in CB$_1$ receptor availability in any of the brain regions studied [17]. It is relevant to note that a hyperactivated state of CB$_1$ receptor in the early stages of AD, followed by a significant decrease as the disease progresses, has been reported, thus suggesting that CB$_1$ receptor might have therapeutic potential in the progression of the disease [18].

Data obtained in mouse models of AD have thus far not been conclusive either. Different groups have reported increases [19], decreases [20], or no changes [21] in CB$_1$ receptor levels in several brain areas (at the mRNA, protein, or receptor coupling efficiency) in the past few years. The current perception is that CB$_1$ receptors may play
a role in the progression of AD, but it is difficult to establish the precise role(s) in which they might contribute. These could range from modifying amyloid processing to protect neurons in the risk of degeneration or to dampen inflammation (see below).

Perhaps, one of the most intriguing aspects of these changes is the profound alteration in the expression pattern of CB$_2$ receptors, which takes place in AD. The analysis of human AD samples by immunohistochemistry revealed the absence of signal for CB$_2$ receptors in brains of the control group (with a limited presence in a subset of microglial cells such as the perivascular microglia) but an intense level of staining in AD samples [22]. Colocalization studies confirmed that CB$_2$ receptors were expressed in microglial cells only, located in the surrounding areas of amyloid-enriched neuritic plaques. However, questions regarding the specificity of antibodies raised against the CB$_2$ receptor [23] made confirmation of these data necessary. Several groups successively provided data supporting the expression of CB$_2$ receptors in microglial cells in the context of AD. Thus, Ramirez et al [24] reported that CB$_2$ receptors were present in microglial cells in human AD samples. More recently, a study in which the expression of CB$_2$ receptors in the brains of two mouse models of AD was analyzed by immunohistochemistry and PET with the specific radiotracer $^{[11]}$C]A836339 confirmed this observation [25]. These authors also used human samples to complete their observations that described the presence of CB$_2$ receptor in not only microglial cells but also astrocytes and neurons. Interestingly, CB$_2$ receptor levels in microglia increased in AD, whereas those in neurons decreased in the disease. These data confirmed the value of CB$_2$ receptors as diagnostic as well as putative therapeutic targets in AD and provided evidence for the expression of CB$_2$ receptors in neurons, a matter of intense controversy. Another recent in vivo study found a decrease in CB$_2$ receptor availability in patients with AD, although this observation could be biased by the affinity of the


radiotracer used toward CB₁ receptor and CB₂ receptor [26]. Finally, by using a newly developed reporter mouse model, we have recently corroborated the selective expression of CB₂ receptor in plaque-associated microglial cells in the 5xFAD mouse model of amyloidosis [27].

Few data are currently available regarding the levels of endocannabinoids and the functional status of their regulatory enzymes in AD. The metabolism of 2-AG and AEA has been shown to be altered in AD, both in human samples as well as in mouse models of the disease, with conflicting results. Thus, although an increase in AEA and 2-AG levels in the 5xFAD model of AD has been reported [28], we were unable to find significant differences in the same animal model [29]. In addition, other authors have reported decreases in 2-AG levels in the AβPPswe/PS₁ΔE9 mouse model of AD [19].

Regarding human samples, a significant decrease in AEA levels and its precursor NArPE, but not 2-AG, in the cortical areas of postmortem brain samples has been reported [30]. Furthermore, this decrease was correlated with the patients’ performance in cognitive tests of psychomotor speed and linguistic ability but not with amyloid plaque density or tau hyperphosphorylation. These data may correlate with those in previous reports in which an induction of the expression of the AEA-degrading enzyme fatty acid amide hydrolase (FAAH) was found in AD samples [22]. In this study, we observed an increase in FAAH immunoreactivity in hypertrophied astrocytes located around the foci of neuroinflammation, such as amyloid plaques. This increase was paralleled by a significant augment in FAAH enzymatic activity in samples obtained by microdissection of amyloid plaques. Finally, Mulder et al [31] used human AD samples to obtain data indicative of an enhanced endocannabinoid signaling, involving mainly 2-AG, around neuritic plaques. This enhancement would be in direct correlation with a
loss of monoacylglycerol lipase (MAGL) enzymatic activity owing to impairment in its recruitment to biological membranes.

Perhaps more difficult to interpret is data obtained from peripheral samples. The analysis of blood plasma revealed no changes in any of the endocannabinoids considered, and their levels showed no correlation with cognitive performance in healthy individuals at risk of AD [32]. Other authors, however, have found a significant increase in 2-AG and the AEA analog N-palmitoyl-ethanolamide levels in the blood plasma of patients with AD [33], and this could reflect a putative protective mechanism in the development of the disease. Interestingly, another report showed that an increase in FAAH mRNA and protein in peripheral blood mononuclear cells of patients with AD was linked to a decrease in the methylation state of the FAAH gene promoter region [34], thus suggesting a facilitation in gene expression. Inhibition of FAAH activity may render positive anti-inflammatory effects in the context of AD.

### 2.2. Preclinical evidence for the therapeutic potential of cannabinoids in Alzheimer's disease

#### 2.2.1. Cannabinoids and Aβ processing

A neuroprotective role for cannabinoids against Aβ has been demonstrated in several *in vitro* and *in vivo* studies. The administration of endocannabinoids such as AEA, 2-AG, and noladin ether, or the supply of endocannabinoid reuptake inhibitors, increased the viability of neurons in culture exposed to different toxic Aβ species [35][36][37][38]. Similarly, exposure to cannabidiol (CBD), possibly the most atypical cannabinoid from a mechanistic perspective [38][39]; the synthetic CB₁ receptor agonist ACEA [40]; the CB₂ receptor selective agonists JWH-015 and JWH-133; or the mixed CB₁/CB₂ receptor agonists ∆⁹-THC, HU-210 and WIN55,212-2 [24][38][41] reduced the Aβ peptide
toxicity *in vitro*. Neuroprotection against Aβ deleterious effects might underlie memory improvement observed after treatment with certain cannabinoids in animal models of AD. Either the elevation of endocannabinoid levels [42] or the administration of synthetic selective CB₁ or CB₂ receptor agonists [43][44][45], or nonspecific CB₁ or CB₂ receptor agonists [24][46][47] or CBD [46], reduced memory impairment in Aβ-injected rodents. Moreover, chronic treatment with ACEA [40], JWH-133 [48][49], WIN55,212-2 [48], CBD [50][51], or with a combination of Δ⁹-THC and CBD [52][53] reduced the cognitive impairment in two different transgenic mouse models of AD.

Multiple mechanisms might participate in neuroprotection against Aβ mediated by cannabinoid compounds, acting in parallel or interacting within them. Apart from the capacity of cannabinoids to indirectly mitigate the harmful effects of Aβ (i.e., inflammation and oxidative stress), which are discussed in the next sections, a direct effect of cannabinoids on Aβ processing has also been reported. Δ⁹-THC directly interacts with Aβ, thereby inhibiting its aggregation [41], and CBD induces the amyloid precursor protein (APP) ubiquitination and the consequent decrease in Aβ production through the activation of PPARγ [54].

CB₂ receptor agonists facilitate Aβ clearance by stimulating the phagocytic activity of macrophages [55][45] and by favoring Aβ transport through the choroid plexus [48]. Similar Aβ clearance across the blood–brain barrier (BBB) was also demonstrated for 2-AG, a synthetic CB₁/CB₂ receptor agonist, and MAGL but not for FAAH inhibitors in *in vitro* and *in vivo* BBB models [56]. The reduction in Aβ levels observed in AD mouse models chronically treated with CB₂ or CB₁/CB₂ receptor agonists [48][28][57] and MAGL inhibitors [28][58] could be explained by the facilitation of Aβ clearance. In line with these observations, the genetic deletion of CB₂ receptors altered the Aβ levels in two different AD models [59][60][61]. By contrast, the specific role of CB₁ receptors...
on Aβ production remains a matter of debate. Whereas some authors reported that specific agonists of this receptor did not alter the Aβ production, aggregation, or clearance in two different transgenic AD models [40][62], others provided evidence about a crosstalk between CB1 receptors and APP. On one hand, deletion of these receptors resulted in reduced APP protein levels and Aβ plaque deposition in APP23 transgenic mice [63] but not in APP/PS1 mice [64]. Furthermore, APP overexpression altered membrane localization and inhibitory signaling activity of CB1 receptors in the hippocampus of Tg2576 mice [65]. On the other hand, the combination of Δ9-THC and CBD, but not each cannabinoid individually, resulted in a reduction in soluble Aβ42 levels, the most toxic form of the Aβ peptide. This activity was CB2 receptor independent and might be achieved by facilitation of Aβ42 deposition in plaques to decrease its toxicity [52][61].

2.2.2. Effects of cannabinoids on tau hyperphosphorylation
Cannabinoids are able to modulate tau hyperphosphorylation, another pathological hallmark of AD. Pioneering studies performed in Aβ-stimulated PC12 neuronal-like cells demonstrated that CBD, ACEA, and WIN 55,212-2 inhibited tau hyperphosphorylation by reducing the active form of glycogen synthase kinase 3β (GSK3β) by direct activation of CB1 receptor [66][67]. In agreement with these studies, a significant reduction in hyperphosphorylated tau levels was reported in the area surrounding Aβ plaques after chronic treatment with ACEA in the APP/PS1 mice [40], likely through the reduction in GSK3β activity as suggested in other studies [41]. Moreover, the same authors revealed a reduction in the activity of different tau kinases in APP/PS1 mice chronically treated with a specific CB2 receptor agonist, lowering tau hyperphosphorylation in neurites closely related to Aβ deposition [49]. By contrast,
deletion of CB$_2$ receptors did not modify tau hyperphosphorylation in dystrophic neurites associated with Aβ plaques in the APP/PS1 mouse [61], although total tau levels were significantly decreased in a different AD mouse model lacking CB$_2$ receptors [59]. According to the hypothesis that suggests a role for cannabinoids in tau phosphorylation, a combination of ∆$_9$-THC and CBD natural extracts reduced the formation of neurofibrillary tangles in parkin null, human tau overexpressing (PK-/-/TauVLW) mice, a model of complex frontotemporal dementia (FTD), parkinsonism, and lower motor neuron disease [70].

2.2.3. Anti-inflammatory effects of cannabinoids

It is currently accepted that the activation of the ECS is part of a neuroprotective response against different types of brain injury, including the appearance of neuritic plaques. The involvement of the ECS is partially based on its anti-inflammatory properties derived of the activation of CB$_1$ and CB$_2$ receptors [24][48] and also of PPAR$_{γ}$ receptors [47][71] by endogenous ligands as well as by phyto and synthetic cannabinoids. As mentioned before, CB$_2$ receptors are upregulated in microglial cells in AD, thus suggesting a role for them in the neuroinflammatory process triggered by amyloid deposition. This role has been described in studies performed both in vivo and in vitro, thus confirming the anti-inflammatory effects associated with CB$_2$ activation (reviewed in [72][73]). Interestingly, these effects are accompanied by improvements in behavioral performance and also by decreased deposition of amyloid plaques, probably owing to a CB$_2$-mediated decrease in cytokine secretion and enhancement of amyloid removal by increased phagocytosis.

However, recent studies suggest that the contribution of this receptor type to AD progression and to the therapeutic effects of certain ECS modulators may be more
complex than initially expected. Thus, the neuroprotective effect of an MAGL inhibitor in APP transgenic mice was independent of CB\textsubscript{2} receptors [74]. Similar results were obtained in APP/PS1 mice treated with a combination of $\Delta^9$-THC and CBD [61]. These results are in agreement with those suggesting a limited role for CB\textsubscript{2} receptors in the progression of AD-like pathology in 5xFAD [75][27] or APP/PS1 mice [61].

One of the most promising approaches for neuroprotection is the indirect enhancement of endocannabinoid levels through the inhibition of MAGL and FAAH [28][29][58][75][74]. Both the pharmacological blockade of MAGL with JZL184 and its genetic inactivation improved behavior, decreased the density of amyloid plaques, and reduced astro- and microgliosis and the production of inflammatory cytokines [58][75]. Interestingly, none of these effects were prevented by CB\textsubscript{1} receptor or CB\textsubscript{2} receptor antagonists but were mediated primarily by alterations in arachidonic acid and/or prostaglandin signaling. As mentioned above, degradation of 2-AG by MAGL has been proposed as a novel pathway for prostaglandin synthesis and a new target to suppress neuroinflammation [76].

Evidence suggests a beneficial effect of FAAH inhibition in animal models of age-related neuroinflammation [29][77]. Murphy et al [77] demonstrated that the selective FAAH inhibitor URB597 reversed the age-linked inflammation in terms of cytokine expression and preserved hippocampal long-term potentiation in aged rats. Pharmacological inhibition of FAAH with URB597 had a limited effect in 5xFAD mice in terms of cytokine expression and behavior, which contrasted with the significant changes observed after genetic inhibition [29]. Interestingly, our data are suggestive of a putative shift in the ECS neurotransmission from a CB\textsubscript{1} receptor-mediated anti-inflammatory action to a pro-inflammatory one, in the context of AD and triggered by a long-term inhibition of FAAH. Paradoxically, this long-term inhibition would also be
beneficial, as mice showed improvements in memory and decreased amyloid deposition. It is still unknown whether these changes involve, for instance, preservation of neuronal morphology in the hippocampus. In any case, it seems to be currently accepted that inhibiting FAAH activity may render positive effects, and in fact, mixed inhibitors for FAAH and other enzymes, i.e., acetylcholinesterase (AChE) or butyrylcholinesterase, are under study to be used as potential therapeutic tools for AD [78][79].

2.2.4. Other effects of cannabinoids
Many studies report different effects of cannabinoids with potential interest for AD. Alterations in the components of the respiratory chain located in the inner mitochondrial membrane that lead to the production of excessive ROS are described in brains affected by AD [80], with subsequent oxidative damage of certain macromolecules that jeopardizes their functionality. Compounds that are able to counteract free radical damage are then assumed to confer neuroprotection, which bestows them potential utility against AD [81]. Among the antioxidant compounds tested in AD models, a few cannabinoids have been included. CBD was the first one to be evaluated. CBD prevented ROS production and lipid peroxidation in PC12 neuronal-like cells exposed to Aβ, reduced apoptosis, and counteracted the Aβ-induced increase in intracellular calcium concentration [39]. CBD also reduced the levels of nitric oxide (NO) and the expression of the inducible NO synthase (iNOS) [67][82]. Mechanisms of action of CBD have been classically assigned to cannabinoid receptor-independent antioxidant properties, a fact derived from its particular chemical structure having two hydroxyl groups. Recent evidence relates this potential to novel nonendocannabinoid signaling mechanisms, e.g., PPAR-γ, Nrf-2 signaling, and adenosine signaling [68]. Recent studies claim for a role of CBD as a negative allosteric modulator of both CB₁ [69] and
CB$_2$ [83] receptors. Although it is unlikely that this capability may underlie its 
antiexcitotoxic, anti-inflammatory, and neuroprotective properties, which are related to 
elevated rather than reduced CB$_1$ and CB$_2$ receptor signaling, these properties may be 
supported by the ability of CBD to increase the activity of mitochondrial complexes in a 
hippocampal cell line [84] in different structures related to AD in the rat brain [85] and 
to rescue memory deficits in rats [86]. However, studies using the mitochondrial 
fraction from the pig brain cortex claim that CBD inhibits the activity of the respiratory 
chain [87][88].

Cannabinoids also exhibited antioxidant properties in *in vivo* models of AD. Thus, The 
selective CB$_2$ receptor agonist JWH-133 reduced hydroxynonenal adducts, derived from 
lipid peroxidation, and enhanced the levels of the superoxide dismutases 1 and 2 in the 
area surrounding Aβ plaques in APP/PS1 mice, thus demonstrating a role for CB$_2$ 
receptors in promoting responses against oxidative stress and reducing its harmful 
consequences [49]. The combination of Δ$_9$-THC and CBD also resulted in a reduction 
of free radicals in a mouse model of tauopathy [70] and in the augmentation of the 
levels of thioredoxin 2 protein, a member of the mitochondrial antioxidant system 
responsible for the clearance of reactive intermediates and the repair of proteins with 
oxidative damage [52].

Certain cannabinoids are known to act on the same targets compared to the current 
medications for AD, i.e., AChE inhibitors and noncompetitive antagonists of the N-
methyl D-aspartate (NMDA) receptor. Δ$_9$-THC competitively inhibits AChE increasing 
acetylcholine availability and prevents AChE-induced Aβ aggregation [89]. CB$_2$ 
receptor agonists exhibit inhibitory effects on butyrylcholinesterase [90]. The synthetic 
cannabinoid HU-211 inhibits NMDA receptors, thereby protecting cells from 
glutamate-induced neurotoxicity [91][92][93]. CB$_1$ receptors mediate neuroprotection
against excitotoxicity by inhibiting presynaptic glutamate release [94] and excessive calcium release [95][96][97]. In agreement with these observations, the combination of Δ⁹-THC and CBD modulated the levels of certain glutamatergic and GABAergic receptors in the cortex of aged APP/PS1 mice, thus suggesting an attempt of these natural cannabinoids to reduce the imbalance of excitatory versus inhibitory neural activity occurring in AD [53].

Additional beneficial effects of cannabinoids in AD include their capacity to prevent Aβ-mediated lysosomal destabilization in cultured neurons, thereby reducing the apoptotic signaling [98]; to promote neurogenesis in response to Aβ insult [82][99]; to normalize the levels of the presynaptic SNAP25 protein involved in aberrant neuritic sprouting in brain areas affected by Aβ [49]; and to induce autophagy facilitating the degradation of aberrant cellular components [70]. Moreover, a recent study revealed that the CB₁/CB₂ mixed agonist WIN 55,212-2 and the CB₂ selective agonist JWH-133 ameliorated the vascular dysfunction in a transgenic model of AD [100]. In addition, a role for CB₂ agonists in stimulating brain glucose uptake was also described in the same animal model [101].

2.3. Therapeutic implications for a cannabinoid-based therapy for Alzheimer’s disease: clinical evidence and future perspectives

Considering the complexity of the pathological mechanisms involved in the progression of AD, compounds such as cannabinoids targeting in parallel several processes that play key roles in AD could offer a more promising therapeutic profile than treatments targeting a single causal or modifying factor. However, as described above, the potential therapeutic utility of cannabinoids in AD is mainly based on the evidence obtained using in vitro and in vivo models. Consequently, there is a need to move the evidence
from the bench to the bed. Nevertheless, it is worth noting that the limited clinical information on the use of cannabinoids in patients with dementia also suggests some beneficial effects. Clinical trials in patients with AD at advanced stages who received an analog of Δ⁹-THC (nabilone or dronabinol) for several weeks showed a significant reduction in agitation and aggression refractory to antipsychotics and anxiolytics, together with weight gain in individuals previously rejecting food, although no reduction in other neuropsychiatric symptoms was observed. Equally important is the almost total absence of side effects observed during treatment with Δ⁹-THC in these patients, and beyond a certain euphoria, drowsiness or fatigue. Despite the limited number of subjects included in the trials and the lack of assessment of cognitive parameters and markers of neurodegeneration, which limits drawing definitive conclusions about the effectiveness of Δ⁹-THC in the treatment of dementia, the available information derived from these studies is relevant and, together with the extensive basic evidence, provides encouragement for conducting controlled clinical trials geared to clarifying the therapeutic potential of cannabinoids in AD.

3. Cannabinoid pharmacology in Parkinson’s disease

PD, the second most common neurodegenerative disease, is a motor disorder affecting 1-2% of the population aged more than 65 years, with an incidence that increases with age. The classic motor symptoms rigidity, bradykinesia, and tremor, are caused by the striatal dopamine deficit generated by the specific loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The SNpc, the striatum (caudate nucleus and putamen), the globus pallidus (internal and external segments, GPi and GPe, respectively), and the substantia nigra pars reticulata (SNpr) are subcortical structures
that are part of the basal ganglia, a group of brain nuclei involved in the control of movement whose activity is primarily affected in PD. The most effective treatment for PD is levodopa (L-dopa), a dopamine replacement therapy that was identified 50 years ago [110]. However, as the disease progresses and more neurons are lost, the efficacy of L-dopa decreases and patients experience motor fluctuations and abnormal involuntary movements known as L-dopa-induced dyskinesia (LID) [111]. The development of new nondopaminergic drugs capable of attenuating motor symptoms without producing dyskinesia is necessary. Ultimately, disease-modifying treatments are needed to stop the neurodegenerative process. On the basis of the cellular location of cannabinoid targets and the neuroprotective activities described for cannabinoids, they represent an interesting therapeutic approach for PD.

Different aspects of the disease can be reproduced in experimental animals. Models based on classic neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), rotenone, paraquat, or lipopolysaccharide (LPS), reproduce the loss of dopaminergic neurons and the motor impairment, thus representing a late-stage model of the disease. Transgenic or knockout genetic models simulate better the pathogenic mechanisms of PD, but their pathological and behavioral phenotype is often quite different from that of the human condition. Similar strategies are used to generate in vitro cellular models [112].

3.1. The Endocannabinoid System in Parkinson’s disease

In agreement with the effect of cannabimimetic drugs on motor activity, different elements of the ECS are abundant in the basal ganglia [113]. The high density of CB₁ receptor immunoreactivity in these nuclei, except for dopaminergic neurons in the SNpc, supports a role for these receptors in the regulation of basal ganglia physiology and pathology [114]. Activation of presynaptic CB₁ receptors in GABAergic and
glutamatergic terminals within basal ganglia leads to presynaptic inhibition of neurotransmitter release [115]. In the striatum, the ECS interacts closely with the dopaminergic system. Activation of postsynaptic dopamine type 2 receptors stimulates AEA release that activates CB₁ receptors in a retrograde manner to downregulate glutamate neurotransmission [116][117]. Although dopaminergic neurons lack CB₁ receptors, they can be activated in a CB₁ receptor-dependent manner by reducing their GABAergic input, thereby favoring dopamine release [118][119]. Cannabinoid receptors and their endogenous ligands are modulated in animal models and patients with PD. CB₁ receptors showed no differential expression in the striatum of 6-OHDA-lesioned rats, but a significant increase in the receptor levels was observed in animals treated with L-dopa [120][121]. A transient increase in CB₁ receptor transcripts in the striatum of the 6-OHDA rats, which was not accompanied by changes in [³H]WIN-55,212-2 binding or [³⁵S]GTPγS stimulation, was described in the striatum, GPe, and SNpr [120][122][123]. [³H]CP-55,940 binding and [³H]WIN-55,212-2 activation of [³⁵S]GTPγS were upregulated in MPTP-lesioned marmosets and returned to control levels upon L-dopa treatment [124]. Interestingly, an increase in CB₁ receptor expression was detected in the basal ganglia of parkinsonian monkeys treated with L-dopa exclusively during the active phase of dyskinesia, CB₁ receptor transcripts returned to control levels when MPTP monkeys were not under the effect of L-dopa [125]. Not only receptor activation but also endocannabinoid levels are altered in experimental models of PD. The levels of AEA, but not 2-AG, were increased in the striatum of the 6-OHDA rat [126]. MPTP-lesioned marmosets showed elevated levels of AEA in the striatum and GPe, and these levels decreased to control levels with L-dopa therapy. 2-AG was increased in the striatum and substantia nigra (SN) but decreased in the GPe; these changes returned to control levels with acute L-dopa.
therapy but persisted when LID was present [127]. Changes in the expression levels of AEA synthesizing/degrading enzymes in the GPe of MPTP monkeys suggest a role for this endocannabinoid as a compensatory mechanism to counteract the dopamine deficit [125]. Changes in the expression of 2-AG synthesizing/degrading enzymes during the active phase of dyskinesia suggest that this endocannabinoid may play a role in LID [125].

Studies carried out with human samples from patients with PD are difficult to interpret because patients are under L-dopa treatment, and most of them do not mention the presence of LID. Therefore, it is not possible to determine whether the observed changes are due to the disease itself, due to the dyskinetic status, or due to the chronic dopaminergic therapy. Analysis of CB\(_1\) receptor transcripts in the postmortem tissue from L-dopa-treated patients with PD showed a downregulation restricted to the anterior-dorsal region of the putamen and to the GPe, thus suggesting that their expression might be modulated heterogeneously in the putamen [128]. A similar study showed an upregulation of CB\(_1\) receptor transcripts in the putamen [129]. The small piece of tissue comprising different regions of the putamen might account for the different observations. The binding of \(^3\)HCP-55,940 was increased in the caudate nucleus and putamen, and the stimulation of \(^{35}\)S\(\text{GTP}\gamma\text{S}\) by \(^3\)HWIN-55,212-2 was high in the caudate nucleus, putamen, GPe, and SN of patients with PD [124]. An interesting study measured CB\(_1\) receptor binding \textit{in vivo} by PET in different groups of patients with PD using the selective radioligand \(^{18}\)F\(\text{MK}-9470\) [130]. An increase in CB\(_1\) receptor availability was displayed in the putamen and a decrease in the SN of patients with PD with regard to controls. In this case, no regional differences were detected between patients with or without LID [130]. Analysis of AEA levels in the cerebrospinal fluid in patients with PD showed that newly diagnosed subjects with PD
and those undergoing a complete L-dopa washout presented higher AEA levels, and these levels were restored to control levels in patients under chronic dopaminergic therapy [131]. Therefore, data obtained from patients with PD and animal models point toward profound rearrangements of the ECS in the basal ganglia after dopamine depletion and with dopamine replacement therapy.

The presence of CB\textsubscript{2} receptors has been demonstrated in activated microglia of the diseased brain [132], thus suggesting that CB\textsubscript{2} receptors are upregulated as part of the activation process. Albeit some limitations, there is evidence of CB\textsubscript{2} receptor expression in striatal fibers and in the SN of rats [133] and in the GPe and GPi of primates [134][135]. There is no consensus regarding the cellular localization of CB\textsubscript{2} receptors in the human brain of patients with PD. A predominant expression of CB\textsubscript{2} receptors has been reported in activated microglia and dopaminergic neurons of SN [136][137]. However, Navarrete et al. (2018) reported a major localization of CB\textsubscript{2} receptors in activated astrocytes [129].

Neuroinflammation is a classical neuropathological hallmark of patients with PD [139][140] and of animal models of the disease. Intrastriatal administration of LPS, 6-OHDA, or rotenone induced an increase in CB\textsubscript{2} receptor mRNA levels that correlated with microglial cell activation [141][142]. In the acute MPTP mouse model, CB\textsubscript{2} receptor was upregulated in microglial cells of the midbrain but not in the striatum [143]. Similar to these results, CB\textsubscript{2} receptor transcripts were upregulated in SN and downregulated in the putamen of parkinsonian patients [129].

These data highlight the potential role played by the ECS in PD pathophysiology and LID and provide an excellent opportunity to develop new therapeutic strategies directed specifically toward different aspects of the disease. Neuronal cannabinoid receptors modulate the main neurotransmitter systems in basal ganglia and offer a target that
might influence motor and nonmotor symptoms of PD or counteract LID. The ability of CB2 receptors to modulate the immune response places them as an interesting therapeutic target for neuroprotection.

3.2. Preclinical evidence for the therapeutic potential of cannabinoids in PD

Animal studies suggest that cannabinoids improve motor symptoms of PD and LID and that they exert neuroprotective effects through cannabinoid receptor-dependent and -independent mechanisms. Because blockade of CB1 receptors facilitates dopamine type 2 receptor-mediated facilitation of movement [116], CB1 receptor antagonists would enhance dopaminergic transmission. Furthermore, one of the classical effects of direct activation of CB1 receptors in rodents is the cannabinoid tetrad, including catalepsy and hypolocomotion [144], which supports the use of CB1 receptor antagonists for akinesia. With regard to this, motor behavior in different 6-OHDA rat models was improved by the CB1 receptor antagonists rimonabant, AM251, and the phytocannabinoid Δ9-tetrahydrocannabivarin (Δ9-THCV) at low doses [145][146][147]. Rimonabt as monotherapy ameliorated parkinsonian symptoms in MPTP primates and reduced LID without compromising L-dopa efficacy [127], although a lack of beneficial effect has also been reported in this animal model [148]. Paradoxically, CB1 receptor agonists improve motor impairment. Administration of either the nonselective cannabinoid receptor agonist CP 55,940 or AM404 to enhance AEA availability into the denervated striatum of 6-OHDA rats had anti-parkinsonian properties [149][150]. Δ9-THC had anti-parkinsonian properties in MPTP-lesioned marmosets, although it induced side effects [151]. From a theoretical perspective, the anti-parkinsonian effect of both CB1 receptor activation and blockade could be explained depending on which nuclei of the basal ganglia are being primarily targeted by the treatment [152]. The different status of the
ECS in the basal ganglia under parkinsonian conditions, dose, gender, trial design, or the extent of the dopaminergic lesion might explain the different efficacy of agonists or antagonists [145][146][151]. The specific localization of CB1 receptors at glutamatergic or GABAergic terminals of neurons in different basal ganglia nuclei [153] and alteration of these pools of receptors under pathological conditions might account for such effects.

Promising data arise from pharmacological studies targeting CB2 receptors. In the 6-OHDA rat model, which has a lower inflammatory response than other PD models, a mild improvement in dopamine levels was detected after the administration of the CB2 receptor agonist HU-308 [154]. Treatment of the acute MPTP mouse model with WIN 55,212-2 before the neurotoxin injection protected dopamine neurons from degeneration in a CB2 receptor-dependent manner, probably through the inhibition of microglial activation. In fact, all CB2 receptor knockout mice died after MPTP administration, thus suggesting that they are critical for protection against the neurotoxin [143]. Similar results were obtained with a lower dose of WIN 55,212-2 and with the CB2 receptor selective agonists JWH-133 and AM1241 [155][156]. Striatal LPS injection induced a mild dopaminergic neurodegeneration and a prominent proinflammatory response. The CB2 receptor selective agonist HU-308 and the CB2 receptor agonist activity of the phytocannabinoid Δ9-THCV protected dopaminergic neurons and decreased the expression of the microglial activation markers CD68 and iNOS in the striatum [137][147]. Interestingly, dopamine neurons in the CB2 receptor knockout mice showed a high vulnerability to LPS and a high degree of macrophage infiltration and astrogliosis in the SN [147][137]. In the rotenone rat model, pretreatment of rats with β-caryophyllene, a phytocannabinoid and selective agonist of CB2 receptor, prevented neurodegeneration and showed anti-inflammatory and antioxidant properties [157].
Biological actions of endocannabinoids are terminated by enzymatic hydrolysis. In the CNS, the MAGL is the main 2-AG-inactivating enzyme and AEA is hydrolyzed by the FAAH [158][159]. Therefore, rather than direct stimulation of cannabinoid receptors with exogenous ligands, an interesting approach is to increase the levels of the endocannabinoids, 2-AG or AEA, by inhibiting their degradation. MAGL inhibition with JZL184 increased 2-AG levels in the brain, improved motor behavior, and exerted neuroprotective effects in the chronic MPTP mouse model [160]. In vitro studies showed that the neuroprotective effect of JZL184 was mediated by CB₂ and not by CB₁ receptors [161]. By contrast, FAAH inhibition with URB597 increased AEA levels in the brain and improved motor behavior but lacked neuroprotective activity [162]. Both, CB₁ and CB₂ receptors were involved in the symptomatic relief exerted by URB597, thus suggesting that it was mediated by neuronal CB₂ receptors probably through CB₁/CB₂ receptor heteromers [162]. The efficacy of dopamine type 2 receptor agonists to improve motor behavior was enhanced by the co-administration of URB597 [163].

Phytocannabinoids have cannabinoid receptor-independent anti-parkinsonian properties. ∆⁹-THC and CBD restored dopamine levels in the 6-OHDA rat model in a CB₁ receptor-independent manner [120], presumably by acting through the same mechanisms (e.g., PPAR-γ, Nrf-2 signaling, thus improving mitochondrial function), and these mechanisms have been described for AD in the previous subsection (see 2.2.4.). However, a lack of neuroprotective activity was described for CBD in the chronic MPTP mouse model [164]. The phytocannabinoid ∆⁹-THCV, with its antioxidant properties and the ability to activate CB₂ and to block CB₁ receptors, presents an interesting pharmacological profile for PD. It protected dopaminergic neurons in the 6-OHDA and in the LPS mice models [147]. An interesting group of cannabinoids are those that bind and activate PPARs [165], a type of intracellular
receptors involved in the control of neuroinflammatory responses [166]. AEA is among the lipids that are considered to be an endogenous ligand for PPARs [167]. Some quinone derivatives of cannabigerol (CBG) such as VCE-003.2 act as PPARγ activators and attenuate the loss of dopaminergic neurons in the LPS mouse model by decreasing the inflammatory response [168]. However, VCE-003.2 failed to protect dopaminergic neurons in the 6-OHDA mouse model, probably because of the poor inflammatory response of the model [168].

3.3. Clinical evidence for the therapeutic potential of cannabinoids in PD and future perspectives.

Clinical trials to test the beneficial effect of cannabinoids in different aspects of PD do not show consistent results. Nabilone, a nonselective CB1 receptor and CB2 receptor agonist, improved LID [169]. Oral administration of a cannabis extract to patients with PD in a randomized, placebo-controlled, crossover study concluded that it did not produce any pro- or anti-parkinsonian effect [170]. By contrast, an open-label observational study showed that smoked cannabis improved motor symptoms of PD such as bradykinesia, tremor, and rigidity and nonmotor symptoms of the disease such as sleep and pain [171]. However, a single dose of smoked marijuana failed to improve tremor, thus suggesting that the anxiolytic action might benefit some patients with tremor when anxiety is an important triggering factor [172]. A subjective improvement in motor symptoms, namely, bradykinesia, rigidity, and tremor, and alleviation of LID was reported in patients with PD who smoked cannabis [173]. However, a different study reported that the main benefit was observed in sleep rather than in motor symptoms [174]. A retrospective study collecting subjective impressions of patients with PD under medical cannabis suggests an improvement in the initial stages of
treatment without major adverse effects [175]. The different outcome of studies using plant extracts could be related to the administration route because cannabinoids are lipid-soluble compounds; hence, oral administration results in lower peak concentrations in plasma than through inhalation. The $\Delta^9$-THC content and the $\Delta^9$-THC:CBD ratio are other parameters to be considered.

These results indicate that targeting the ECS might be useful in the treatment of PD symptoms or dyskinesias. Further clinical studies involving large samples of patients, placebo groups, appropriate molecular targets, and objective outcome measures are necessary to clarify the effectiveness of cannabinoid-based therapies.

The potential role played by the ECS in PD provides an excellent opportunity to develop new therapeutic strategies aimed at different aspects of the disease. Although an enormous effort has been made in understanding the elements of the ECS, further studies are necessary to unravel the functional significance of the system under physiological and pathological conditions. The complex interplay between the main neurotransmitter systems in the basal ganglia and the modulatory role of the ECS, mainly through CB$_1$ receptors, might provide the base for the development of nondopaminergic therapies or alleviation of LID. Among the different cannabinoid targets, stimulation of CB$_2$ receptors, either directly or by increasing endogenous cannabinoids, might offer an interesting disease-modifying alternative and a nondopaminergic therapy for the disease.

The inconsistent effect of some cannabinoid receptor ligands could be attributed to their functional selectivity to induce specific conformational changes in the receptors modulating different intracellular signaling pathways [176][177]. Furthermore, cannabinoid receptors can form heteromers with other G-protein-coupled receptors generating new signaling entities that contribute to the heterogeneity of their responses.
The use of CB$_1$ receptor antagonists has been successfully investigated in preclinical models, but the only clinical trial using rimonabant for the hypokinetic symptoms in PD failed [180]. However, this trial recruited patients with PD who all responded well to L-dopa, and it is possible that rimonabant could be a better option for those patients who do not respond to classic dopaminergic replacement therapy (approximately 30%). While an attempt to directly target CB$_1$ receptors seems an improbable clinical approach for PD, manipulation of endogenous levels of AEA and 2-AG or compounds targeting different receptors may be a promising strategy. Further research is needed to define multiple opportunities for manipulating this system in movement disorders.

4. Cannabinoid pharmacology in Huntington's disease

The key clinical symptoms in HD are choreic movements, which are produced by the degeneration of striatal medium-sized spiny neurons projecting to the GPe and SN [181]. The disease is also accompanied by behavioral disturbances and dementia, which are caused by the deterioration of specific neurons located in cortical structures [182]. These two neuronal subpopulations are the most vulnerable cells affected in this genetic pathology and the first to deteriorate [181][182][183]. However, the disease may ultimately affects other neuronal subpopulations in different CNS structures such as the cerebellum [183]. From a molecular perspective, HD is an inherited disorder caused by mutations in the gene encoding the regulatory protein huntingtin. The mutation consists in an excessive number of CAG repeats in the first exon, and this leads to a polyglutamine trait in the amino terminal end, thus causing a variety of anomalies in its cellular function [184]. HD is the most prevalent polyglutamine disorder, which also includes other diseases such as autosomal dominant hereditary ataxias [185]. The key
neuropathological feature in HD is the formation of inclusions of the mutant huntingtin, with ubiquitin and other proteins. These inclusion bodies are located predominantly in the cell nucleus producing a transcriptional dysregulation of key genes like BDNF [186]. With lower frequency, huntingtin inclusions are also found in the cytosol and in the neurites, thereby pointing out the damage observed in mitochondria and cytoskeleton, respectively [184]. The disease can be recapitulated in laboratory animals, including predominantly mice (e.g., R6/1, R6/2, HD94, and YAC128) and also other vertebrates (e.g., zebrafish) or invertebrates (Drosophila and Caenorhabditis elegans) by means of transgenes containing the human mutant huntingtin, and also in cells transfected with these mutant forms. Additional models may be generated by intrastriatal or systemic administration of excitotoxins or mitochondrial toxins (e.g., inhibitors of mitochondrial complex II) (see [187] for a review on experimental models). Pharmacological therapies for patients with HD are extremely limited and circumscribed to the treatment of choreic movements. Currently, the only agent licensed is the inhibitor of the vesicular monoamine transporter-1 tetrabenazine (Xenazine®) [188]. Some antioxidants, minocycline, histone deacetylase inhibitors, and unsaturated fatty acids have been or are being investigated at the clinical level [188][189]. Cannabinoids were included in the list of neuroprotective agents investigated for HD early in the 2000s [190], although they had already been investigated as symptom-relieving agents [191]. In both cases, the research reached the clinical scenario [192][193][194][195][196][197].

4.1. The endocannabinoid system in Huntington’s disease

Numerous changes in the endocannabinoid elements, affecting mainly CB1 and CB2 receptors and the hydrolyzing enzymes, have been described in brain samples from patients with HD and animal models. A key observation in postmortem tissues derived
from patients with HD [198] and in different transgenic animal models [199][200][201][202][203] was the early defects in striatal CB₁ receptor signaling with a progressive loss of these receptors, which was evident even before neuronal death and the occurrence of choreic symptoms. An early stimulation of the CB₁ receptors located in striatal projecting neurons dampened their impairment, thus improving their capacity to inhibit the excitotoxic events that initiate the damage and to regulate growth factor generation that promotes striatal neuron survival [204].

Downregulation of CB₁ receptors might be caused by a loss of function of the mutant huntingtin in its capacity to sequestrate the gene silencing factor REST to the cytoplasm, which facilitates its translocation to the nucleus and the inhibition of different genes including BDNF and Cnr1 [205]. Other studies described equivalent effects exerted through the inhibition of the ability of the mutant huntingtin to regulate other transcriptional modulators such as CREB-binding protein/CREB or NFκB-p65/Re1A acting at the promoter of the CB₁ receptor gene [206]. Despite the relationship between the reduction in CB₁ receptors and the mutant huntingtin, an early impairment in CB₁ receptor coupling to G proteins was observed days before the onset of the striatal degeneration in an experimental model generated by neurotoxin administration, the rat lesioned with the irreversible mitochondrial complex II inhibitor 3-nitropropionate [207]. Further studies conducted in R6/2 transgenic mice described that, the loss of CB₁ receptors within the basal ganglia was evident in striatal projecting neurons, but it was preserved in corticostriatal neurons. The relationship between CB₁ receptor expression and neuronal vulnerability suggests that this receptor pool constitutes a promising target for neuroprotective therapeutic strategies [208][209]. These observations modified the initial idea that the potential benefits of CB₁ receptor activation are restricted at early stages of the disease and provided the basis for a therapeutic intervention at
intermediate and advanced stages of the neurodegenerative process [210][209]. Although this question needs to be investigated, a recent study has demonstrated that the activation of corticostriatal CB₁ receptors protects striatal neurons projecting to the SN, but not those projecting to the GPe, against different insults [211]. The expression of CB₂ receptors is also altered in patients with HD and animal models. In rats lesioned with malonate, a reversible complex II inhibitor applied directly into the striatum [212]; genetic mouse models [213][214]; and postmortem tissue from patients with HD [213], CB₂ receptors were overexpressed in activated astrocytes and microglial cells recruited to the lesioned site [212][213][214]. One study conducted with human HD tissue samples failed to detect CB₂ receptor expression in astrocytes and microglial cells but located this receptor in endothelial cells [215]. Alteration in cannabinoid receptors in HD shows consistent results among different experimental models, neurotoxin-based or transgenic model, and human samples. The deficit of CB₁ receptors clearly represents an alteration that contributes to HD progression by promoting excitotoxic damage and growth factor deficiency. CB₂ receptor expression increases during the progression of the disease, and it appears to be more of an endogenous protective response.

Endocannabinoid levels were also markedly reduced in the brain in experimental models of HD [216][217]. By contrast, the R6/2 transgenic mouse model presented an increase in FAAH levels [205][218]. Recent studies in patients with HD identified an increase in endocannabinoid levels in the blood due to a reduction in FAAH activity [219], thus suggesting that changes related to FAAH levels and activity in human patients may be different from those in animal models. A reduction in the level of this enzyme in patients with HD may be interpreted as an endogenous protective response to promote elevated AEA levels. The elevation of FAAH levels found in R6/2 mice may
be part of the pathogenesis supporting the interest of exploring the possibilities of therapies based on FAAH inhibition for HD [205][218].

4.2. Preclinical evidence for the therapeutic potential of cannabinoids in Huntington’s disease

The positive results obtained in a broad spectrum of animal models of HD confirmed the benefits of specific cannabinoids against different cytotoxic stimuli reproduced in the experimental models [220][14]. The cannabinoid receptor agonist WIN 55,212,2 protected striatal neurons in a rat model that relies on quinolinate-induced excitotoxic damage [204]. CB₁ receptor activation with Δ⁹-THC in the genetic model of the disease R6/2 mice attenuated striatal neuron loss, whereas striatal degeneration was aggravated in R6/2 mice with a genetic deficiency in CB₁ receptors [205]. The genetic rescue of CB₁ receptors using viral approaches recovered striatal synapses, although it was ineffective for the motor impairment [221]. The genetic ablation of the CB₁ receptor in other HD murine transgenic model or following 3-nitropropionate intoxication yielded equivalent results [222].

Cannabinoids that activate the CB₂ receptors selectively are also effective in HD, acting preferentially on inflammatory events and microglial activation in rats lesioned with malonate [212] in R6/2 mice [213] and following the excitotoxic lesion with quinolinate in mice [213]. The treatment of R6/1 transgenic mice with low doses of the nonselective synthetic agonist WIN 55,212-2 prevented the development of motor deficits and preserved striatal projecting neurons, although the study did not specified whether these effects were CB₁ and/or CB₂ receptor dependent [223]. However, administration of the nonselective cannabinoid agonists either HU-210 or Δ⁹-THC to R6/1 mice lacked beneficial effects [224], whereas the FAAH inhibitor URB597 did not restore motor
impairment but improved CB₁ striatal expression [224]. Differences in doses or agonists might account for such differences.

Antioxidant nonpsychoactive phytocannabinoids CBD and CBG have also been investigated in experimental models of HD, although their effects are independent of CB₁ and CB₂ receptors. CBD was neuroprotective in rats intoxicated with 3-nitropropionate, a model characterized by mitochondrial damage, oxidative stress, and calpain activation [225]. By contrast, it was inactive in malonate-lesioned rats, a HD model with a pro-inflammatory component [212]. CBG was neuroprotective in the R6/2 and the 3-nitropropionate-lesioned mice [226]. The effect of CBD and CBG might be mediated by the activation of nonendocannabinoid targets such as PPARs or by the other mechanisms indicated before for CBD (see subsection 2.2.4). The quinone derivative of CBG VCE-003.2, which activates PPARγ improved neuronal survival against the neurotoxicity caused by the mutant huntingtin and quinolinate in vitro, and against quinolinate and 3-nitropropionate in vivo [227]. Based on these broad-spectrum effects of cannabinoids in HD in experimental models, a combination of CBD with ∆⁹-THC, as in the cannabinoid-based medicine Sativex®, was studied in animal models of HD [210]. This combination preserved striatal neurons in the neurotoxin-induced models, the malonate-lesioned mouse [228], and the 3-nitropropionate-lesioned rat [229]. In R6/2 mice, only ∆⁹-THC in the form of botanical extract showed a beneficial effect [230].

4.3. Clinical evidence for the therapeutic potential of cannabinoids in Huntington’s disease and future perspectives

The first clinical trials with cannabinoids in HD were conducted in the 1990s and examined whether CBD [192][231] or the ∆⁹-THC synthetic analog nabilone [193] may
improve choreic movements. However, an aggravation of these movements was reported \[192][231][193]. Nabilone was beneficial on chorea and behavioral disturbances in a case report study \[194\] and in a pilot clinical study \[195\]. Recently, a clinical study investigated the effect of different cannabinoid formulations, Sativex®, nabilone, or dronabinol on dystonia, a frequent symptom in HD \[232\], and patients experienced motor improvements mainly in dystonia and presented less irritability and apathy \[197\]. These clinical studies conducted with cannabinoids were focused on symptom relief.

With regard to neuroprotectant effects, the positive results obtained in experimental animals with the combination of CBD and $\Delta^9$-THC supported to test whether Sativex® may serve as a disease-modifying therapy for patients with HD \[196\]. The trial was conducted in Spain and was the first trial designed to test a neuroprotective strategy. Although Sativex® was safe and well-tolerated in patients with HD, unfortunately, it failed to provide evidence that it may slow down disease progression in HD \[196\]. Such failure may be related to the relatively short time, 12 weeks, for the active treatment and an unexpected prolonged placebo effect \[196\], thus suggesting the need for additional clinical testing using longer periods of treatments.

Therefore, the major challenges for cannabinoid-based therapies in HD are to find the appropriate cannabinoid formulations and to implement clinical trial designs to correlate the benefits observed in the preclinical models with a positive effect in patients with HD. A formulation with a single cannabinoid with a broad-spectrum profile might render a positive outcome, but a formulation based on the combination of cannabinoids with different activities would be better. In fact, this was the reason to select Sativex® \[196\]. To test disease-modifying therapies, a new trial design with long periods for the active
treatment versus placebo would be necessary to reveal a neuroprotective effect in patients with HD treated with Sativex® or similar preparations [196].

5. Cannabinoid pharmacology in Amyotrophic Lateral Sclerosis

ALS is a progressive neurodegenerative disease predominantly affecting the upper and lower motor neurons leading to muscle denervation, atrophy, and paralysis [233]. The most abundant form of the disease is sporadic [234]. Approximately, 20% of patients present a hereditary form of ALS, which is associated with mutations in genes encoding for the key antioxidant enzyme superoxide dismutase-1 (SOD-1), and the proteins involved in pre-mRNA splicing, transport, and stability of TAR-DNA-binding protein-43 (TDP-43) or FUS (fused in sarcoma) protein [233][235]. More recently, a CCGGGG hexanucleotide expansion was described in the C9orf72 gene, which represents most of the cases of familial ALS [236]. It encodes a protein involved in intracellular trafficking in neurons and other cell functions not completely understood [237]. Familial and sporadic forms of ALS are clinically and histopathologically indistinguishable, sharing pathogenic events and therapeutic intervention. In the case of some ALS-related genes, TARDBP (encoding TDP-43), FUS, or C9orf72, the disease can be accompanied by features of FTD, which supports the idea that, rather than being one disorder, ALS belongs to a broad spectrum of disorders ranging from motor to cognitive deficits [238]. As in other neurodegenerative disorders, the damage of upper and lower motor neurons occurs by the combination of excitotoxicity, chronic inflammation, oxidative stress, protein aggregation, and other cytotoxic events [239][240][235]. A characteristic feature in ALS pathogenesis is the extreme vulnerability of the axonal transport of proteins or cell organelles owing to their excessive axonal length of motor neurons [241].

Experimental models for the study of ALS include predominantly transgenic mice
overexpressing mutated forms of the different ALS-related genes (e.g., SOD-1, TARDBP, and C9orf72) [242]. The disease still lacks an effective treatment for symptoms and/or disease progression. For a long time, the antiexcitotoxic agent riluzole (Rilutek®) was the only approved drug [243]. More recently, the antioxidant agent edavarone (Radicava®) and the tyrosine kinase inhibitor masitinib [244] have been approved (or designed as orphan drugs) for the treatment of patients with ALS. Solid evidence derived from studies describing the changes in specific elements of the ECS in the spinal cord, brainstem, and motor cortex, the CNS areas more affected in patients with ALS and in animal models, placed cannabinoids as a possible and potential disease-modifying therapy in ALS [245][246].

5.1. The endocannabinoid system in Amyotrophic Lateral Sclerosis

The levels of the endocannabinoids AEA and 2-AG are elevated in the spinal cord of SOD-1 mutant mice [247][248]. This was paralleled by an increase in the expression of NAPE-PLD, but no changes were observed in DAGL nor in FAAH and MAGL [249]. Increased levels of 2-AG in the spinal cord of these mice have been interpreted as an endogenous protective response, fueling the idea that inhibiting endocannabinoid-inactivating enzymes may be neuroprotective in ALS [250]. CB₂ receptors experienced an important upregulatory response in the spinal cord of SOD-1 mutant [251][249], TDP-43 transgenic [252] mice, in an ALS-related canine neurodegenerative pathology [253] and in patients with ALS [254][255]. This upregulation appears to occur predominantly in astrocytes recruited at lesioned sites in mutant SOD-1 mice (unpublished results), dogs with degenerative myelopathy [253], and postmortem primary motor cortex samples from patients with ALS [255]. CB₂ receptor expression was upregulated in activated microglia in spinal grey and white matter areas in TDP-43
transgenic mice [252] and in *postmortem* spinal cord samples from patients with ALS [254]. These observations suggest that beneficial effects may be obtained by selectively targeting this receptor in the control of astrocyte support or microglial toxicity for motor neurons. Changes in the expression of CB$_1$ receptors in animal models are inconclusive. A study reported downregulatory responses in the spinal cord of SOD-1 mutant mice, even at early presymptomatic phases [256], thus suggesting that it may predispose motor neurons to excitotoxic events, but these observations were not validated in the same mutant mice [249]. No changes in CB$_1$ receptor expression were reported in the TDP-43 transgenic mice [252]. In the spinal cord of patients with ALS, CB$_1$ receptors appear to be reduced [257].

5.2. Preclinical and clinical evidence for the therapeutic potential of cannabinoids in Amyotrophic Lateral Sclerosis

Most pharmacological studies on the use of cannabinoids in experimental ALS were conducted in the classic transgenic mouse that overexpresses a mutated form (G93A) of SOD-1 despite mutations in this enzyme representing only a small percentage of ALS cases. The model was developed in the 1990s and was used to investigate the neuroprotective effects of Δ$^9$-THC [258], cannabinol (CBN) [259], WIN 55,212-2 [248], and the selective CB$_2$ agonist AM1241 [260][251], in all cases with beneficial effects. Similar findings were obtained from double mutants generated by crossing mutant SOD-1 mice with mice deficient in endocannabinoid genes FAAH or CB$_1$ knockout mice [248]. These results reinforced not only the interest in using CB$_1$ receptor agonists but also the elevation of endocannabinoid levels with FAAH inhibitors. Inhibition of MAGL in the same mutant SOD-1 mouse model delayed disease onset and progression and improved animal survival, probably through the reduction in proinflammatory
cytokines and the elevation of BDNF in the spinal cord [250]. These effects were also reproduced in vitro [250]. Recent studies have extended the cannabinoid pharmacology to the new transgenic mouse model of TDP-43 (A315T). Activation of CB\textsubscript{2} receptors improved motor behavior, preserved spinal motor neurons, and attenuated glial reactivity [261]. CB\textsubscript{1} receptor activation also decreased glial reactivity but to a lower extent [261].

Clinical evidence for the use of cannabinoids in ALS is scarce. The first studies were exclusively observational, based on subjective impressions of patients with ALS who self-medicated with cannabis, and the results suggested a mild improvement for different symptoms [262]. A randomized, double-blind, crossover trial conducted with oral Δ\textsuperscript{9}-THC showed that although the drug was well tolerated in patients, it failed to decrease the frequency and intensity of cramps [263][264]. No clinical studies have been attempted to investigate the potential of cannabinoids as disease-modifying therapies. There is an urgent need for additional clinical investigations in ALS, and cannabinoids might represent an interesting therapeutic approach [245].

5.3. Therapeutic implications for a cannabinoid-based therapy for Amyotrophic Lateral Sclerosis

Research in cannabinoid-based neuroprotective therapies in ALS has been circumscribed to the preclinical level supporting the relevance of CB\textsubscript{2} receptor activation on astrocyte trophic support, microglial reactivity, and neuroinflammation. It also involves certain CB\textsubscript{1} receptor-mediated effects that might contribute to attenuate excitotoxic damage [265]. Cannabinoids with antioxidant properties (e.g., Δ\textsuperscript{9}-THC, CBN) exerting a cannabinoid receptor-independent mechanism of action (perhaps related to PPAR-γ signaling) offer an interesting therapeutic alternative, but preclinical
studies are needed before reaching the clinic [265]. In this context, the potential of a Sativex-like combination of botanical extracts enriched in ∆⁹-THC and CBD was investigated in postsymptomatic SOD-1 mutant mice [249]. However, this combination provided a poor neurological recovery and no changes in animal survival [249], thus suggesting the need for additional cannabinoid combinations that demonstrate to be effective in preclinical models and that may be translated to the clinical scenario.

6. Conclusions and future perspectives

Cannabinoids are compounds with a broad spectrum of effects, which makes them suitable to target the multiple pathological features that characterize neurodegenerative diseases (Fig. 2). Currently, compounds with multiple targets or combinations of cannabinoids with different activities are being investigated. Preclinical studies provide evidence to support the potential of cannabinoid pharmacology for the treatment of these conditions. Each neurodegenerative disease has specific alterations of the ECS that will provide specific substrates for a cannabinoid-based therapy. With regard to this, an interesting experimental therapy for AD would be a 1:1 combination of ∆⁹-THC:CBD because of the synergy existing between the mechanisms of action for each natural cannabinoid. The administration of both compounds was more effective than each single cannabinoid in reducing the cognitive decline and certain pathological processes. Moreover, available clinical data about the chronic use of a combination of ∆⁹-THC and CBD for other indications suggest that it might result in a safe and well-tolerated treatment for patients with AD and a virtual absence of the side effects commonly associated with the psychotropic properties of ∆⁹-THC owing to the capacity of CBD to counteract them. Interesting preclinical alternatives for the treatment of PD would be targeting CB₂ receptors, as well as the modulation of endocannabinoid levels
through the inhibition of their catabolic enzymes MAGL, which is neuroprotective, and FAAH. The phytocannabinoid Δ⁹-THCV with its particular profile has emerged as a valuable alternative, which needs to be further investigated. On the basis of the promising data on experimental models of HD, activation of CB₁ and CB₂ receptors would be the targets of choice for cannabinoid-based therapies, whereas cannabinoids targeting both receptors and also PPARγ would be the best option in ALS. Different strategies have been tested, directly targeting cannabinoid receptors with agonists or antagonists, or indirect modulation of the endocannabinoid signaling with inhibitors of endocannabinoid degradation or activation of cannabinoid receptor independent effects.

In fact, further research is needed to investigate one of the most interesting aspects of cannabinoid pharmacology, their neuroprotective profile, probably owing to their pleiotropic activity. The profound rearrangements experienced by the ECS during the time course of neurodegenerative diseases are specific for each disease and may vary through the different stages of the degenerative process. Because ECS changes are not homogeneous along the disease course and affect neuronal subsets differentially, similar therapeutic effects might be observed with drugs producing opposing actions or the same compound might produce both, thus amelioration or worsening of symptoms. An additional level of complexity is attributed to the functional selectivity of cannabinoids [177]. Different receptor agonists induce specific changes in receptor conformation, thereby activating different signaling pathways. Therefore, each class of cannabinoid receptor ligand needs to be evaluated separately for therapeutic efficacy. An important consideration that requires an in-depth investigation is the ability of cannabinoid receptors to form heteromers with other receptors generating unique signaling units that cannot be achieved by the individual receptors [153]. These heteromers contribute to the heterogeneity of cannabinoid receptor signaling and provide novel pharmacological
targets. PPARγ is one of the most relevant targets for CBD and other cannabinoids and a key element for exerting anti-inflammatory and neuroprotective properties [68]. The recent formulation of CBD as Epidiolex® (GW Pharmaceuticals, UK), which was approved by the Food and Drug Administration for the treatment of infantile refractory epileptic syndromes, may facilitate the use of this cannabinoid in clinical trials for neurodegenerative disorders.

Consequently, further research is needed to identify the precise formulation for each type of pathology and each subset of patients as well as for achieving a neuroprotective effect. New clinical studies involving large samples of patients, placebo groups, appropriate molecular targets, and objective outcome measures are necessary to clarify the effectiveness of cannabinoid-based therapies.
Acknowledgments

MA and MAA are supported by the grant PI17/01931 from the Spanish Government (ISCIII-FEDER). JR and RT are supported by Ministerio de Economía y Competitividad (SAF2016/75959-R), GW Pharmaceuticals and Universidad Francisco de Vitoria (UFV2017). JFR and JAR are supported by grants from CIBERNED (CB06/05/0089), MINECO (SAF2015-68580-C2-1-R), GW Pharmaceuticals, and VivaCell-Emerald.

Declaration of authors’ competing interests

The authors declare they have no potential conflict of interest in relation to this submission.
References


[54] C. Scuderi, L. Steardo, G. Esposito, Cannabidiol promotes amyloid precursor...


S. Montanari, L. Scalvini, M. Bartolini, F. Belluti, S. Gobbi, V. Andrisano, A. Ligresti, V. Di Marzo, S. Rivara, M. Mor, A. Bisi, A. Rampa, Fatty Acid Amide


Figure legends

**Figure 1**: Versatility of the endocannabinoid system (ECS) elements to counteract the effects of aging and neurodegeneration. The ECS modulates common traits of neurodegeneration counteracting neuronal death, oxidative stress, neuroinflammation, or abnormal protein accumulation. The key location of the different ECS elements within the brain enables modulation of crucial processes for the correct balance between neuron survival and degeneration. Neurons express preferentially CB\(_1\) receptors involved in the regulation of neurotransmitter release. During the degenerative process, these receptors experience important alterations that may contribute to neuronal death. Resting microglia express low levels of CB\(_2\) receptors, and the levels were upregulated under pathological conditions. Targeting these receptors modulates neuroinflammatory responses. Astrocytes express low levels of CB\(_1\) receptors. Upon activation, they may modify the expression of either CB\(_1\) or CB\(_2\) receptor. The different cell types have the machinery for endocannabinoid biosynthesis, 2-arachidonoylglycerol (2-AG), or anandamide (AEA), thus contributing to the endocannabinoid tone of the brain. The specific contribution of each cell type may vary under different pathological conditions.

**Figure 2**: Broad-spectrum profile of cannabinoids for the treatment of different neuropathological traits of neurodegenerative diseases. Beneficial effects of cannabinoid-based therapies determined from animal models of Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS). Modulation in microglial immune responses showed a therapeutic response in AD, PD, HD, and ALS models. The antioxidant properties of cannabinoids were beneficial in animal models of AD and HD. In models of AD, targeting the endocannabinoid system successfully improved synaptic plasticity and prevented Aβ
aggregation and toxicity. Glutamatergic excitotoxicity was reversed by cannabinoid
treatment in animal models of AD and HD. Endocannabinoid signaling modulation
provides neuroprotection and disease modification in experimental models of PD, HD,
and ALS.